BCAL Diagnostics introduces multi-cancer test in Sydney, Melbourne

Full story: https://grafa.com/en/news/australia/bcal-diagnostics-introduces-multi-cancer-test-in-sydney-melbourne

BCAL Diagnostics introduced the Avantect blood-based test in Australia to screen for eight cancer types.
The company's stock remained unchanged following the product rollout announcement.
The commercialisation strategy targets national expansion following initial rollouts in Sydney and Melbourne.

BCAL Diagnostics (ASX:BDX) has commenced the Australian rollout of the Avantect Multi-Cancer blood-based diagnostic test in Sydney and Melbourne.

The phased launch provides local patients access to non-invasive testing capable of detecting signals across eight distinct cancer types alongside organ-of-origin indicators.

BCAL CEO Anne-Louise Arnett said, “The direction of cancer diagnostics is increasingly towards earlier, less-invasive detection, and blood-based testing has a role to play in that shift.”

The company reported that validation study results demonstrated an overall sensitivity of 56.2% and a specificity of 98.4% across all analysed cancer types.

Initial processing of Australian patient samples will take place at ClearNote Health's US laboratory before testing expands nationally through local clinical networks.

The addition expands the firm's early detection lineup to four blood-based tests while leveraging established clinical referral pathways.

Following the announcement the BCAL Diagnostics share price was unchanged at $0.082.

The organisation focuses on commercialising liquid biopsy technology to improve early disease detection rates across clinical settings.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":610865460138168,"tweetId":"610865460138168","gmtCreate":1790156263442,"gmtModify":1790156270529,"author":{"id":4169784042383112,"idStr":"4169784042383112","authorId":4169784042383112,"authorIdStr":"4169784042383112","name":"Grafa","avatar":"https://community-static.tradeup.com/news/ec1614006170d0aa3182195a94e8944d","vip":2,"userType":2,"introduction":"Grafa generates AI-driven data, news and analysis about NYSE, Nasdaq and ASX stocks","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":255,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://community-static.tradeup.com/news/d17f039c75d7bb59dd245ae52a56579c","width":"1456","height":"816"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/d17f039c75d7bb59dd245ae52a56579c","width":"1456","height":"816"}],"title":"BCAL Diagnostics introduces multi-cancer test in Sydney, Melbourne","html":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/d17f039c75d7bb59dd245ae52a56579c\" tg-width=\"1456\" tg-height=\"816\"></p>\n<p>Full story: https://grafa.com/en/news/australia/bcal-diagnostics-introduces-multi-cancer-test-in-sydney-melbourne</p>\n<ul>\n <li>\n  <p>BCAL Diagnostics introduced the Avantect blood-based test in Australia to screen for eight cancer types.</p></li>\n <li>\n  <p>The company's stock remained unchanged following the product rollout announcement.</p></li>\n <li>\n  <p>The commercialisation strategy targets national expansion following initial rollouts in Sydney and Melbourne.</p></li>\n</ul>\n<p style=\"text-align: start;\">BCAL Diagnostics (ASX:BDX) has commenced the Australian rollout of the Avantect Multi-Cancer blood-based diagnostic test in Sydney and Melbourne.</p>\n<p style=\"text-align: start;\">The phased launch provides local patients access to non-invasive testing capable of detecting signals across eight distinct cancer types alongside organ-of-origin indicators.</p>\n<p style=\"text-align: start;\">BCAL CEO Anne-Louise Arnett said, “The direction of cancer diagnostics is increasingly towards earlier, less-invasive detection, and blood-based testing has a role to play in that shift.”</p>\n<p style=\"text-align: start;\">The company reported that validation study results demonstrated an overall sensitivity of 56.2% and a specificity of 98.4% across all analysed cancer types.</p>\n<p style=\"text-align: start;\">Initial processing of Australian patient samples will take place at ClearNote Health's US laboratory before testing expands nationally through local clinical networks.</p>\n<p style=\"text-align: start;\">The addition expands the firm's early detection lineup to four blood-based tests while leveraging established clinical referral pathways.</p>\n<p style=\"text-align: start;\">Following the announcement the BCAL Diagnostics share price was unchanged at $0.082.</p>\n<p style=\"text-align: start;\">The organisation focuses on commercialising liquid biopsy technology to improve early disease detection rates across clinical settings.</p></body></html>","htmlText":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/d17f039c75d7bb59dd245ae52a56579c\" tg-width=\"1456\" tg-height=\"816\"></p>\n<p>Full story: https://grafa.com/en/news/australia/bcal-diagnostics-introduces-multi-cancer-test-in-sydney-melbourne</p>\n<ul>\n <li>\n  <p>BCAL Diagnostics introduced the Avantect blood-based test in Australia to screen for eight cancer types.</p></li>\n <li>\n  <p>The company's stock remained unchanged following the product rollout announcement.</p></li>\n <li>\n  <p>The commercialisation strategy targets national expansion following initial rollouts in Sydney and Melbourne.</p></li>\n</ul>\n<p style=\"text-align: start;\">BCAL Diagnostics (ASX:BDX) has commenced the Australian rollout of the Avantect Multi-Cancer blood-based diagnostic test in Sydney and Melbourne.</p>\n<p style=\"text-align: start;\">The phased launch provides local patients access to non-invasive testing capable of detecting signals across eight distinct cancer types alongside organ-of-origin indicators.</p>\n<p style=\"text-align: start;\">BCAL CEO Anne-Louise Arnett said, “The direction of cancer diagnostics is increasingly towards earlier, less-invasive detection, and blood-based testing has a role to play in that shift.”</p>\n<p style=\"text-align: start;\">The company reported that validation study results demonstrated an overall sensitivity of 56.2% and a specificity of 98.4% across all analysed cancer types.</p>\n<p style=\"text-align: start;\">Initial processing of Australian patient samples will take place at ClearNote Health's US laboratory before testing expands nationally through local clinical networks.</p>\n<p style=\"text-align: start;\">The addition expands the firm's early detection lineup to four blood-based tests while leveraging established clinical referral pathways.</p>\n<p style=\"text-align: start;\">Following the announcement the BCAL Diagnostics share price was unchanged at $0.082.</p>\n<p style=\"text-align: start;\">The organisation focuses on commercialising liquid biopsy technology to improve early disease detection rates across clinical settings.</p></body></html>","text":"Full story: https://grafa.com/en/news/australia/bcal-diagnostics-introduces-multi-cancer-test-in-sydney-melbourne BCAL Diagnostics introduced the Avantect blood-based test in Australia to screen for eight cancer types. The company's stock remained unchanged following the product rollout announcement. The commercialisation strategy targets national expansion following initial rollouts in Sydney and Melbourne. BCAL Diagnostics (ASX:BDX) has commenced the Australian rollout of the Avantect Multi-Cancer blood-based diagnostic test in Sydney and Melbourne. The phased launch provides local patients access to non-invasive testing capable of detecting signals across eight distinct cancer types alongside organ-of-origin indicators. BCAL CEO Anne-Louise Arnett said, “The direction of cancer diagnostics is increasingly towards earlier, less-invasive detection, and blood-based testing has a role to play in that shift.” The company reported that validation study results demonstrated an overall sensitivity of 56.2% and a specificity of 98.4% across all analysed cancer types. Initial processing of Australian patient samples will take place at ClearNote Health's US laboratory before testing expands nationally through local clinical networks. The addition expands the firm's early detection lineup to four blood-based tests while leveraging established clinical referral pathways. Following the announcement the BCAL Diagnostics share price was unchanged at $0.082. The organisation focuses on commercialising liquid biopsy technology to improve early disease detection rates across clinical settings.","highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/610865460138168","repostId":0,"isVote":1,"tweetType":1,"viewCount":21,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1404,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/610865460138168"}